semaglutide ending End of Compounded Semaglutide; 464M Teens Will Have Obesity; GLP-1 Scripts Skyrocket FDA ends semaglutide shortage, closing

Rare But Serious Risks Pancreatitis: Occurs in a small percentage of patients regardless of sex

SAFETY, TOLERABILITY, AND SPECIAL POPULATIONS The overall safety profile of GLP-1 RAs and multi-agonists is well-characterized from large clinical trials and real-world data

This finding was noteworthy considering the short followup period

Jolanda van Hal Nutrition Insight reviews 2025: AI tech, personalized solutions, and nutrition security in the GLP-1 era Jolanda van Hal Key takeaways This year, AI became a practical engine for nutrition, powering personalization, speeding R&D and bioactive discovery, and improving clinical research

Using cloudy peptide introduces uncontrolled variables that compromise reproducibility and scientific validity

Common Early Semaglutide Side Effects and Duration Nausea remains the most frequently reported side effect, appearing in up to 40% of patients within the first two weeks and typically resolving or significantly improving by week 68